Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo

Cell Death and Differentiation

Volumn 21, Issue 6, 2014, Pages 956-966

  Phesse, T J ^a,b,c,d   Myant, K B ^e   Cole, A M ^e   Ridgway, R A ^a   Pearson, H ^f   Muncan, V ^f   Van Den Brink, G R ^e   Vousden, K H ^g   Sears, R ^h   Vassilev, L T ^a   Clarke, A R ^e   Sansom, O J ^e  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h HOFFMANN LA ROCHE INC   (United States)

Author keywords

apoptosis; DNA damage; in vivo; MDM2; MYC; P53

Indexed keywords

CISPLATIN; PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3; MYC PROTEIN; MYC PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; GENE DELETION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; IN VIVO STUDY; INTESTINE CELL; INTESTINE CRYPT; IONIZING RADIATION; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DEGRADATION; RADIOSENSITIVITY; SPLEEN; THYMUS; UPREGULATION; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; RADIATION RESPONSE;

MURINAE;

ANIMALS; APOPTOSIS; CELL SURVIVAL; CISPLATIN; DNA DAMAGE; ENTEROCYTES; HUMANS; MICE; PROTO-ONCOGENE PROTEINS C-MYC; RADIATION, IONIZING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899926214     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.15     Document Type: Article

References (48)

1. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991; 6: 1915-1922.
2. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119-128.
3. Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene 2008; 27: 6462-6472.
4. Hermeking H, Eick D. Mediation of c-Myc-induced apoptosis by p53. Science 1994; 265: 2091-2093.
5. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002; 109: 321-334.
6. Finch A, Prescott J, Shchors K, Hunt A, Soucek L, Dansen TB et al. Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. Cancer Cell 2006; 10: 113-120.
7. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13: 2658-2669.
8. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999; 13: 2670-2677.
9. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA et al. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008; 14: 447-457.
10. Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002; 419: 729-734.
11. Mitchell KO, Ricci MS, Miyashita T, Dicker DT, Jin Z, Reed JC et al. Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res 2000; 60: 6318-6325.
12. Barsyte-Lovejoy D, Mao DY, Penn LZ. C-Myc represses the proximal promoters of GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism. Oncogene 2004; 23: 3481-3486.
13. Rogulski K, Li Y, Rothermund K, Pu L, Watkins S, Yi F et al. Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway. Oncogene 2005; 24: 7524-7541.
14. Maclean KH, Keller UB, Rodriguez-Galindo C, Nilsson JA, Cleveland JL. C-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol Cell Biol 2003; 23: 7256-7270.
15. Cannell IG, Kong YW, Johnston SJ, Chen ML, Collins HM, Dobbyn HC et al. p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc Natl Acad Sci USA 2010; 107: 5375-5380.
16. Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev 2011; 25: 907-916.
17. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455: 679-683.
18. Muncan V, Sansom OJ, Tertoolen L, Phesse TJ, Begthel H, Sancho E et al. Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc. Mol Cell Biol 2006; 26: 8418-8426.
19. Sansom OJ, Zabkiewicz J, Bishop SM, Guy J, Bird A, Clarke AR. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogene 2003; 22: 7130-7136.
20. Sansom OJ, Clarke AR. P53 null mice: damaging the hypothesis? Mutat Res 2000; 452: 149-162.
21. Bettess MD, Dubois N, Murphy MJ, Dubey C, Roger C, Robine S et al. C-Myc is required for the formation of intestinal crypts but dispensable for homeostasis of the adult intestinal epithelium. Mol Cell Biol 2005; 25: 7868-7878.
22. Ireland H, Kemp R, Houghton C, Howard L, Clarke AR, Sansom OJ et al. Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of beta-catenin. Gastroenterology 2004; 126: 1236-1246.
23. Marshman E, Ottewell PD, Potten CS, Watson AJ. Caspase activation during spontaneous and radiation-induced apoptosis in the murine intestine. J Pathol 2001; 195: 285-292.
24. Sansom OJ, Clarke AR. The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice. Oncogene 2002; 21: 5934-5939.
25. Clarke AR, Gledhill S, Hooper ML, Bird CC, Wyllie AH. p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 1994; 9: 1767-1773.
26. Peukert K, Staller P, Schneider A, Carmichael G, Hanel F, Eilers M. An alternative pathway for gene regulation by Myc. Embo J 1997; 16: 5672-5686.
27. Wilkins JA, Sansom OJ. C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine. Cancer Res 2008; 68: 4963-4966.
28. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007; 446: 676-679.
29. Pusapati RV, Rounbehler RJ, Hong S, Powers JT, Yan M, Kiguchi K et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci USA 2006; 103: 1446-1451.
30. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000; 10: 886-895.
31. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-206.
32. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-208.
33. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888-1893.
34. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007; 13: 23-31.
35. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
36. Wang X, Cunningham M, Zhang X, Tokarz S, Laraway B, Troxell M et al. Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res 2011; 71: 925-936.
37. Ashton GH, Morton JP, Myant K, Phesse TJ, Ridgway RA, Marsh V et al. Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling. Dev Cell 2010; 19: 259-269.
38. Myant K, Sansom OJ. Wnt/Myc interactions in intestinal cancer: partners in crime. Exp Cell Res 2011; 317: 2725-2731.
39. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA 2005; 102: 731-736.
40. Saxena A, Rorie CJ, Dimitrova D, Daniely Y, Borowiec JA. Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. Oncogene 2006; 25: 7274-7288.
41. Cao X, Bennett RL, May WS. C-Myc and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis. J Biol Chem 2008; 283: 14490-14496.
42. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011; 108: 16669-16674.
43. Luche H, Weber O, Nageswara Rao T, Blum C, Fehling HJ. Faithful activation of an extra-bright red fluorescent protein in "knock-in" Cre-reporter mice ideally suited for lineage tracing studies. Eur J Immunol 2007; 37: 43-53.
44. de Alboran IM, O'Hagan RC, Gartner F, Malynn B, Davidson L, Rickert R et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 2001; 14: 45-55.
45. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-684.
46. Vooijs M, Jonkers J, Berns A. A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent. EMBO R 2001; 2: 292-297.
47. Zhang X, Farrell AS, Daniel CJ, Arnold H, Scanlan C, Laraway BJ et al. Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc Natl Acad Sci USA 2012; 109: 2790-2795.
48. Bjerknes M, Cheng H. Methods for the isolation of intact epithelium from the mouse intestine. Anat Rec 1981; 199: 565-574.